TriangleObinutuzumab (NCT06252675)
Obinutuzumab trial for Mantle Cell Lymphoma (NCT06252675). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory mantle-cell lymphoma after an anti-CD20 antibody and alkylating chemotherapy. Progression on a covalent BTK inhibitor or prior CD20/CD3 bispecific therapy excludes participation.
The idea: start obinutuzumab, then glofitamab infusions, adding daily pirtobrutinib tablets in cycle two. Obinutuzumab targets CD20; glofitamab connects T cells to CD20-bearing lymphoma cells; pirtobrutinib blocks BTK growth signaling. Researchers first assess safety, then complete responses. Some patients may stop treatment after a deep response.
This phase 2 study plans 30 patients. Madhav Seshadri leads four recruiting California sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.